LONDON — Prolifix Ltd., focused on the discovery and development of small-molecule drugs that modulate the cell cycle, has replaced its CEO, Peter Lewis, after less than one year. Lewis was the first permanent CEO to be appointed since the company was formed in 1994, around intellectual property from the government-funded Medical Research Council. Lewis was formerly the research director of British Biotech plc, of Oxford, U.K.
Lewis will be replaced by Birgit Stattin-Norinder, who joins the company from Pharmacia & Upjohn, of London, where she was senior vice president of worldwide product development. — Nuala Moran